Alternative Data for Scisparc
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 2,566 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 36 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,591 | Sign up | Sign up | Sign up |
| X Followers | 638 | Sign up | Sign up | Sign up |
| X Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 4 | Sign up | Sign up | Sign up |
About Scisparc
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
| Price | $4.02 |
| Target Price | Sign up |
| Volume | 31,637 |
| Market Cap | $3.1M |
| Year Range | $4.02 - $73.71 |
| Dividend Yield | 0% |
| PE Ratio | 0 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trailsMarch 10 - GlobeNewswire |
|
 |
Which stocks are moving on Tuesday?March 10 - ChartMill |
 |
Stay updated with the stocks that are on the move in today's pre-market session.March 9 - ChartMill |
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesMarch 3 - Benzinga |
|
SciSparc announces 1-for-9 reverse share splitMarch 3 - Yahoo Entertainment |
|
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News PendingMarch 3 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 460,000 | 290,000 | 170,000 | -9.3M | -7.9M | |
| Q2 '25 | 0 | 0 | 0 | 0 | 0 | |
| Q1 '25 | 470,000 | 430,000 | 32,000 | -2.8M | -3.7M | -6.200 |
| Q4 '24 | 0 | 0 | 0 | 0 | 0 | |
| Q3 '24 | 840,000 | 370,000 | 470,000 | -3.4M | -3.3M | -1.700 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Scisparc (SPRC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Scisparc
The Market Cap of Scisparc is $3.1M.
As of today, Scisparc's PE (Price to Earnings) ratio is 0.
Currently, the price of one share of Scisparc stock is $4.02.
The SPRC stock price chart above provides a comprehensive visual representation of Scisparc's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Scisparc shares. Our platform offers an up-to-date SPRC stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Scisparc (SPRC) does not offer dividends to its shareholders. Investors interested in Scisparc should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Scisparc are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
